CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificialCAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

2026/02/06 21:31
5 min read

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company’s Cambridge, Massachusetts office.

In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico’s oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company’s growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.

Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.

She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.

Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

“Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico’s oncology programs,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients.”

“I am excited to join Insilico Medicine at such an important stage of growth,” said Dr. Zhang. “Insilico’s unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients.”

Over the past year, Insilico Medicine’s oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential “best-in-class” inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.

In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico’s AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround – from project initiation to preclinical candidate (PCC) nomination – of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Cision View original content:https://www.prnewswire.com/news-releases/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development–oncology-302681141.html

SOURCE Insilico Medicine

Market Opportunity
MASS Logo
MASS Price(MASS)
$0.0003298
$0.0003298$0.0003298
+3.32%
USD
MASS (MASS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

X Üst Düzey Yetkilisi, Platformda Kripto Paralar İçin Müjdeyi Verdi! Ancak Bazı Altcoinler İçin Kötü Haber Olabilir

X Üst Düzey Yetkilisi, Platformda Kripto Paralar İçin Müjdeyi Verdi! Ancak Bazı Altcoinler İçin Kötü Haber Olabilir

X Ürün Lideri ve Solana ekosistem danışmanı Nikita Bier, sosyal medya platformu X’te kripto para kullanımının artmasını desteklediğini ancak spam ve tacizi teşvik
Share
Coinstats2026/02/14 23:11
China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

The post China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise appeared on BitcoinEthereumNews.com. China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise China’s internet regulator has ordered the country’s biggest technology firms, including Alibaba and ByteDance, to stop purchasing Nvidia’s RTX Pro 6000D GPUs. According to the Financial Times, the move shuts down the last major channel for mass supplies of American chips to the Chinese market. Why Beijing Halted Nvidia Purchases Chinese companies had planned to buy tens of thousands of RTX Pro 6000D accelerators and had already begun testing them in servers. But regulators intervened, halting the purchases and signaling stricter controls than earlier measures placed on Nvidia’s H20 chip. Image: Nvidia An audit compared Huawei and Cambricon processors, along with chips developed by Alibaba and Baidu, against Nvidia’s export-approved products. Regulators concluded that Chinese chips had reached performance levels comparable to the restricted U.S. models. This assessment pushed authorities to advise firms to rely more heavily on domestic processors, further tightening Nvidia’s already limited position in China. China’s Drive Toward Tech Independence The decision highlights Beijing’s focus on import substitution — developing self-sufficient chip production to reduce reliance on U.S. supplies. “The signal is now clear: all attention is focused on building a domestic ecosystem,” said a representative of a leading Chinese tech company. Nvidia had unveiled the RTX Pro 6000D in July 2025 during CEO Jensen Huang’s visit to Beijing, in an attempt to keep a foothold in China after Washington restricted exports of its most advanced chips. But momentum is shifting. Industry sources told the Financial Times that Chinese manufacturers plan to triple AI chip production next year to meet growing demand. They believe “domestic supply will now be sufficient without Nvidia.” What It Means for the Future With Huawei, Cambricon, Alibaba, and Baidu stepping up, China is positioning itself for long-term technological independence. Nvidia, meanwhile, faces…
Share
BitcoinEthereumNews2025/09/18 01:37
Kalshi Launches Blockchain Ecosystem Hub with Solana and Base Partnership

Kalshi Launches Blockchain Ecosystem Hub with Solana and Base Partnership

The regulated prediction market platform Kalshi announced today the launch of KalshiEco Hub, a new initiative partnering with Solana and Coinbase's Base network to drive blockchain-based prediction market innovation.
Share
Brave Newcoin2025/09/18 06:15